Aptabio Therapeutics, Inc. operates as a pharmaceutical biotechnology company that develops intractable innovative drugs based on original platform technology. It offers selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company was founded by Su-Jin Lee on July 24, 2009 and is headquartered in Yongin, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company